CDK Global, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CDK Global, Inc. (CDK) provides integrated data and technology solutions, including dealer management systems (DMS), customer relationship management (CRM) tools, digital marketing platforms, and business intelligence services, primarily to automotive retailers, heavy truck dealers, recreation vehicle operators, and heavy equipment businesses in North America. The company offers its flagship CDK Dealership Xperience platform, an open and integrated SaaS solution that streamlines sales, service, inventory management, financing, parts supply, repair workflows, and customer experiences; additional suites encompass fixed operations tools, Neuron data intelligence, digital retailing capabilities, and payment processing integrations, serving nearly 15,000 retail locations across the United States and Canada. Founded in 2014 as a spin-off from ADP Dealer Services with roots tracing to 1972, CDK Global maintains its global headquarters in Hoffman Estates, Illinois, with key operations in Austin, Texas, and an expanded engineering facility in Hyderabad, India. In July 2022, Brookfield Business Partners and institutional partners acquired CDK Global for $8.3 billion, taking the company private and enabling a sharper focus on North American automotive retail technology. Recent developments include the September 2025 expansion of its Hyderabad facility by 50,000 square feet to accelerate AI-driven product innovation, such as enhancements to the Dealership Xperience platform and fixed operations suite now extended to non-CDK DMS customers; in December 2024, CDK secured a $500 million incremental credit facility to support growth initiatives. The company continues to pursue strategic partnerships with dealer groups, including providing its platform to Benzel-Busch Family of Dealerships, Car Pros Automotive Group, and others in Michigan, Tennessee, New York, and Ohio, while advancing cloud-based solutions for omnichannel retail commerce.
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Tekion Files Lawsuit Against CDK Global's Anticompetitive Practices
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Asbury Automotive Wins Preliminary Injunction Against CDK Global LLC
CDK Extends Relationship With Sonic Automotive
Asbury Automotive Group: Looking Past The CDK Outage
CDK Expects to Have Hacked Systems Restored by July 4
CDK Global says some U.S. car dealerships are back up after last week's cyberattack
CDK Cyberattack Throws Auto Retailers Into Operational Chaos
Asbury Automotive Group Provides Update on Service Impacts Related to the CDK Cyber Incident
Group 1 Automotive says CDK cyberattack had disrupted business applications and processes at U.S. operations that rely on its systems
Group 1 Automotive Provides Statement on CDK Cybersecurity Incident
These Stocks Could Benefit From the CDK Cyberattack
CDK Extends Relationship With Group 1 Automotive
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
Astar Network and Sequence Team up to Launch Astar Studio, a Specialized Platform for Developers With a $200K Grant Program